This article was originally posted Feb. 14.

NEW YORK (GenomeWeb News) – The Institute for Cancer Research, London plans to launch a new center that will conduct genomic profiling of patients' cancer tumors, and it wants to raise £3.2 million ($5.1 million) to fund the venture.

NEW YORK (GenomeWeb News) – Two new loci have been linked to elevated risk for a childhood embryonal kidney cancer called Wilms tumor, according to a study appearing online yesterday in Nature Genetics.

Using an RNA interference screen that relies on massively parallel sequencing, British researchers have identified new genes that seem to contribute to sensitivity or resistance to the breast cancer drug tamoxifen.

The partners will perform genome-wide screens to look for weak spots in cancer cells that could be targeted by anti-cancer drugs.

Two independent research teams have used copy number and other genomic analyses to characterize cancer genomes.

The collaboration comes as the ICR embarks on a "network medicine" approach to cancer research that focuses on how cancer cell networks interact with each other and other tissues.

AstraZeneca and Cancer Research UK will contribute a combined £5.6 million ($8.9 million) to the Institute of Cancer Research to discover and develop cancer drugs that target molecular chaperones. AstraZeneca will have an exclusive worldwide license to compounds developed during the collaboration.

The IT firm will equip the London cancer research group with its computing needs for a period of at least five years.


Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.